Ishikawa H, Nakao K, Matsumoto K, Nishimura D, Ichikawa T, Hamasaki K, Eguchi K
The First Department of Internal Medicine, Nagasaki University School of Medicine, Sakamoto, Nagasaki, Japan.
Gut. 2004 Jun;53(6):884-9. doi: 10.1136/gut.2003.026047.
Recent studies indicated that hepatic stem cells in the bone marrow could differentiate into mature hepatocytes, suggesting that bone marrow cells could be used for replacement of damaged hepatocytes in a variety of liver diseases. Hepatocellular carcinoma (HCC) is thought to arise from hepatic stem cells. In this study, we investigated the malignant potential of hepatic stem cells derived from the bone marrow in a mouse model of chemical hepatocarcinogenesis.
Bone marrow cells were obtained from the male beta-galactosidase (beta-gal) transgenic mouse and transplanted into female recipient mice. Hepatocarcinogenesis was induced by a year of treatment with diethylnitrosamine and phenobarbital (NDEA/PB). One year later, the liver was removed from each treated mouse and evaluated by x-gal staining, immunohistochemistry, and fluorescence in situ hybridisation (FISH).
Forty per cent of recipient mice survived and developed multiple HCC. Clusters of beta-gal positive mature hepatocytes were detected sporadically in the entire liver of NDEA/PB treated mice who underwent bone marrow transplantation (BMT) with while no such hepatocytes were identified in the liver of BMT mice that were not treated with NDEA/PB. The Y chromosome was detected with the same frequency as the donor male liver in clusters of beta-gal positive mature hepatocytes by FISH. However, no HCC was positive for beta-gal or the Y chromosome. Immunohistochemically, beta-gal positive mature hepatocytes did not express CD34 or alpha-fetoprotein.
Our results suggest that hepatic stem cells derived from the bone marrow have low malignant potential, at least in our model.
近期研究表明,骨髓中的肝干细胞可分化为成熟肝细胞,这提示骨髓细胞可用于替代多种肝病中受损的肝细胞。肝细胞癌(HCC)被认为起源于肝干细胞。在本研究中,我们在化学性肝癌发生的小鼠模型中,研究了源自骨髓的肝干细胞的恶性潜能。
从雄性β-半乳糖苷酶(β-gal)转基因小鼠获取骨髓细胞,并将其移植到雌性受体小鼠体内。通过用二乙基亚硝胺和苯巴比妥(NDEA/PB)处理一年诱导肝癌发生。一年后,从每只接受处理的小鼠身上取出肝脏,通过X-gal染色、免疫组织化学和荧光原位杂交(FISH)进行评估。
40%的受体小鼠存活并发生了多发性HCC。在接受骨髓移植(BMT)且用NDEA/PB处理的小鼠的整个肝脏中,偶尔检测到β-gal阳性成熟肝细胞簇,而在未用NDEA/PB处理的BMT小鼠肝脏中未发现此类肝细胞。通过FISH在β-gal阳性成熟肝细胞簇中检测到Y染色体的频率与供体雄性肝脏相同。然而,没有HCC对β-gal或Y染色体呈阳性。免疫组织化学检测显示,β-gal阳性成熟肝细胞不表达CD34或甲胎蛋白。
我们的结果表明,至少在我们的模型中,源自骨髓的肝干细胞具有较低的恶性潜能。